154 related articles for article (PubMed ID: 17490774)
1. Enhanced pharmacological activity of recombinant human interleukin-11 (rhIL11) by chemical modification with polyethylene glycol.
Takagi A; Yamashita N; Yoshioka T; Takaishi Y; Sano K; Yamaguchi H; Maeda A; Saito K; Takakura Y; Hashida M
J Control Release; 2007 Jun; 119(3):271-8. PubMed ID: 17490774
[TBL] [Abstract][Full Text] [Related]
2. Incorporation into a biodegradable hyaluronic acid matrix enhances in vivo efficacy of recombinant human interleukin 11 (rhIL11).
Takagi A; Yamashita N; Yoshioka T; Takaishi Y; Nakanishi K; Takemura S; Maeda A; Saito K; Takakura Y; Hashida M
J Control Release; 2006 Oct; 115(2):134-9. PubMed ID: 16973236
[TBL] [Abstract][Full Text] [Related]
3. Effect of divalent polyethylene glycol units, conjugated on human granulocyte colony-stimulating factor, on biological activities in vitro and in vivo.
Yamasaki M; Asano M; Yokoo Y; Okabe M
Drugs Exp Clin Res; 1998; 24(4):191-6. PubMed ID: 10051965
[TBL] [Abstract][Full Text] [Related]
4. Polyethylene-glycol conjugated recombinant human acetylcholinesterase serves as an efficacious bioscavenger against soman intoxication.
Kronman C; Cohen O; Raveh L; Mazor O; Ordentlich A; Shafferman A
Toxicology; 2007 Apr; 233(1-3):40-6. PubMed ID: 17045722
[TBL] [Abstract][Full Text] [Related]
5. Engineering an arginine catabolizing bioconjugate: Biochemical and pharmacological characterization of PEGylated derivatives of arginine deiminase from Mycoplasma arthritidis.
Wang M; Basu A; Palm T; Hua J; Youngster S; Hwang L; Liu HC; Li X; Peng P; Zhang Y; Zhao H; Zhang Z; Longley C; Mehlig M; Borowski V; Sai P; Viswanathan M; Jang E; Petti G; Liu S; Yang K; Filpula D
Bioconjug Chem; 2006; 17(6):1447-59. PubMed ID: 17105223
[TBL] [Abstract][Full Text] [Related]
6. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs.
Chen SA; Sawchuk RJ; Brundage RC; Horvath C; Mendenhall HV; Gunther RA; Braeckman RA
J Pharmacol Exp Ther; 2000 Apr; 293(1):248-59. PubMed ID: 10734176
[TBL] [Abstract][Full Text] [Related]
7. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.
Tsutsumi Y; Kihira T; Tsunoda S; Kamada H; Nakagawa S; Kaneda Y; Kanamori T; Mayumi T
J Pharmacol Exp Ther; 1996 Sep; 278(3):1006-11. PubMed ID: 8819479
[TBL] [Abstract][Full Text] [Related]
8. Schedule dependency of the antitumor activity and toxicity of polyethylene glycol-modified interleukin 2 in murine tumor models.
Zimmerman RJ; Aukerman SL; Katre NV; Winkelhake JL; Young JD
Cancer Res; 1989 Dec; 49(23):6521-8. PubMed ID: 2819708
[TBL] [Abstract][Full Text] [Related]
9. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic.
Bell SJ; Fam CM; Chlipala EA; Carlson SJ; Lee JI; Rosendahl MS; Doherty DH; Cox GN
Bioconjug Chem; 2008 Jan; 19(1):299-305. PubMed ID: 18020402
[TBL] [Abstract][Full Text] [Related]
10. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
[TBL] [Abstract][Full Text] [Related]
11. Accelerated clearance of polyethylene glycol-modified proteins by anti-polyethylene glycol IgM.
Cheng TL; Wu PY; Wu MF; Chern JW; Roffler SR
Bioconjug Chem; 1999; 10(3):520-8. PubMed ID: 10346886
[TBL] [Abstract][Full Text] [Related]
12. Modification of allergenicity and immunogenicity of formate dehydrogenase by conjugation with linear mono methoxy poly ethylene glycol: improvement in detoxification of formate in methanol poisoning.
Muthuvel A; Rajamani R; Senthilvelan M; Manikandan S; Sheeladevi R
Clin Chim Acta; 2006 Dec; 374(1-2):122-8. PubMed ID: 16919615
[TBL] [Abstract][Full Text] [Related]
13. Physicochemical and pharmacokinetic characterization of highly potent recombinant L-methionine gamma-lyase conjugated with polyethylene glycol as an antitumor agent.
Takakura T; Takimoto A; Notsu Y; Yoshida H; Ito T; Nagatome H; Ohno M; Kobayashi Y; Yoshioka T; Inagaki K; Yagi S; Hoffman RM; Esaki N
Cancer Res; 2006 Mar; 66(5):2807-14. PubMed ID: 16510603
[TBL] [Abstract][Full Text] [Related]
14. PEGylated recombinant human tumor necrosis factor alpha: preparation and anti-tumor potency.
Li YP; Pei YY; Ding J; Shen ZM; Zhang XY; Gu ZH; Zhou JJ
Acta Pharmacol Sin; 2001 Jun; 22(6):549-55. PubMed ID: 11747763
[TBL] [Abstract][Full Text] [Related]
15. Chemical modification of recombinant human keratinocyte growth factor 2 with polyethylene glycol improves biostability and reduces animal immunogenicity.
Huang Z; Ni C; Chu Y; Wang S; Yang S; Wu X; Wang X; Li X; Feng W; Lin S
J Biotechnol; 2009 Jul; 142(3-4):242-9. PubMed ID: 19477206
[TBL] [Abstract][Full Text] [Related]
16. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.
Yang Z; Wang J; Lu Q; Xu J; Kobayashi Y; Takakura T; Takimoto A; Yoshioka T; Lian C; Chen C; Zhang D; Zhang Y; Li S; Sun X; Tan Y; Yagi S; Frenkel EP; Hoffman RM
Cancer Res; 2004 Sep; 64(18):6673-8. PubMed ID: 15374983
[TBL] [Abstract][Full Text] [Related]
17. Effect of polyethylene glycol modification on the circulatory stability and immunogenicity of recombinant human butyrylcholinesterase.
Chilukuri N; Sun W; Naik RS; Parikh K; Tang L; Doctor BP; Saxena A
Chem Biol Interact; 2008 Sep; 175(1-3):255-60. PubMed ID: 18603232
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and Pharmacodynamic Evaluation of Different PEGylated Human Interleukin-11 Preparations in Animal Models.
Yu KM; Yiu-Nam Lau J; Fok M; Yeung YK; Fok SP; Hu TL; Tsai YJ; Choo QL
J Pharm Sci; 2018 Nov; 107(11):2755-2763. PubMed ID: 30005986
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor potency of polyethylene glycolylated tumor necrosis factor-alpha: a novel polymer-conjugation technique with a reversible amino-protective reagent.
Tsunoda S; Ishikawa T; Yamamoto Y; Kamada H; Koizumi K; Matsui J; Tsutsumi Y; Hirano T; Mayumi T
J Pharmacol Exp Ther; 1999 Jul; 290(1):368-72. PubMed ID: 10381801
[TBL] [Abstract][Full Text] [Related]
20. PEGylation of interleukin-6 effectively increases its thrombopoietic potency.
Tsutsumi Y; Tsunoda S; Kamada H; Kihira T; Kaneda Y; Ohsugi Y; Mayumi T
Thromb Haemost; 1997 Jan; 77(1):168-73. PubMed ID: 9031469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
